HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

JIANGXI BIO

6.370

+0.0701.11%

Volume:1.46M

Turnover:9.36M

Market Cap:1.96B

PE:- -

High:7.060

Open:6.300

Low:6.020

Close:6.300

52wk High:10.750

52wk Low:6.020

Shares:308.38M

HK Float Shares:307.00M

Volume Ratio:0.09

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

ROE:21.04%

ROA:12.08%

PB:3.41

PE(LYR):- -

PS:7.22

Loading ...

Overview Company News Filings

Jiangxi Institute of Biological Products Sets Final Offer Price Under Global Offering at Hk$11.2 Per H Share

Jiangxi Bio Unit Wins China Nod for Veterinary Tetanus Antitoxin

MT Newswires Live

Movement Alert｜Jiangxi Biologics Rises 9.52% in Regular Trading, Subsidiary Obtains Veterinary Tetanus Antitoxin Product Approval

JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin

Jiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline

Bulletin Express

Jiangxi Institute of Biological Products - Subsidiary Obtains Approval Certificate for Veterinary Tetanus Antitoxin

THOMSON REUTERS

Movement Alert｜Jiangxi Biologics Falls 17.86% in Regular Trading, IPO Debut Breaks Below Issue Price on First Day of Listing

Jiangxi Institute of Biological Products Slumps 34% in Hong Kong Debut

MT Newswires Live

Jiangxi Bio Prices Hong Kong IPO at Midpoint, Raises HK$339 Million

MT Newswires Live

JIANGXI BIO Makes Debut on Exchange with Significant Early Drop, Holding Leading Global TAT Market Position

Stock Track | JIANGXI BIO Plummets 21.43% at Market Open as Hong Kong Debut Opens Well Below IPO Price

Jiangxi Bio Sets Final IPO Price at HK$11.2 per Share, Hong Kong Public Offering Heavily Oversubscribed

Jiangxi Institute of Biological Products - Final Offer Price Under Global Offering Set at Hk$11.2 Per H Share

THOMSON REUTERS

New Stock Pre-Listing Trading: JIANGXI BIO (06915) Drops Over 10% Initially, Resulting in a Loss per Board Lot

Jiangxi Bio Releases Updated Articles of Association Detailing Governance Structure, Share Capital and Dividend Framework

Bulletin Express

JIANGXI BIO Releases Updated Audit Committee Charter to Strengthen Governance and Oversight

Bulletin Express

Jiangxi Bio Sets Out Strategy and Investment Committee Mandate to Bolster Governance Ahead of Hong Kong Listing

Bulletin Express

Initial Public Offering Update: JIANGXI BIO (06915) Subscription Period Concludes with HK$10.4 Billion in Margin Financing, Oversubscribed 219 Times

Jiangxi Bio's Hong Kong IPO: Dominant Market Share Fails to Mask Profitability Challenges, Rising VAT and Single-Product Reliance Weigh on Outlook

Jiangxi Institute of Biological Products Seeks Up to HK$473 Million in Hong Kong IPO

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06915/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06915","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06915\",,,,,undefined,":{"symbol":"06915","market":"HK","secType":"STK","nameCN":"JIANGXI BIO","latestPrice":6.37,"timestamp":1783066093470,"preClose":6.3,"halted":0,"volume":1455500,"delay":0,"changeRate":0.011111111111111157,"floatShares":307000000,"shares":308377319,"eps":0,"marketStatus":"Closed","change":0.07,"latestTime":"07-03 16:08:13","open":6.3,"high":7.06,"low":6.02,"amount":9364125,"amplitude":0.165079,"askPrice":6.37,"askSize":10500,"bidPrice":6.31,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.34,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"listingDate":1782748800000,"exchange":"SEHK","adjPreClose":6.3,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.090463,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06915\",,,,,undefined,":{"symbol":"06915","floatShares":307000000,"roa":"12.08%","roe":"21.04%","lyrEps":0,"volumeRatio":0.090463,"shares":308377319,"dividePrice":0,"high":7.06,"amplitude":0.165079,"preClose":6.3,"low":6.02,"week52Low":6.02,"pbRate":"3.41","psRate":"7.22","week52High":10.75,"institutionHeld":0,"latestPrice":6.37,"committee":-0.826087,"eps":0,"divideRate":0,"volume":1455500,"delay":0,"ttmEps":0.34,"open":6.3,"prevYearClose":11.2,"prevWeekClose":11.2,"prevMonthClose":9.78,"prevQuarterClose":9.78,"fiveDayClose":11.2,"twentyDayClose":11.2,"sixtyDayClose":11.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06915\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06915\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06915\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06915\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06915","date":"2026-07-02","current":18.735294,"percent":1,"low":17.750558,"twenty":17.750558,"median":17.750558,"eighty":17.750558,"high":17.750558,"avg":17.750558,"sd":0,"marketCap":1942777109},"quantilePoints":[{"date":"2026-07-02","current":17.750558,"twenty":17.750558,"median":17.750558,"eighty":17.750558,"marketCap":1942777109}],"updateTime":1783082525528},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06915\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648966325","title":"Jiangxi Institute of Biological Products Sets Final Offer Price Under Global Offering at Hk$11.2 Per H Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2648966325","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648966325?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:10","pubTimestamp":1783077016,"startTime":"0","endTime":"0","summary":"June 29 (Reuters) - Jiangxi Institute of Biological Products Inc <6915.HK>::*FINAL OFFER PRICE UNDER GLOBAL OFFERING SET AT HK$11.2 PER H SHARE*Further company coverage: 6915.HK* ((Reuters.Briefs@thom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nRSD74KT8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648653305","title":"Jiangxi Bio Unit Wins China Nod for Veterinary Tetanus Antitoxin","url":"https://stock-news.laohu8.com/highlight/detail?id=2648653305","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648653305?lang=en_us&edition=fundamental","pubTime":"2026-07-03 12:51","pubTimestamp":1783054273,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products'  wholly owned subsidiary, Chifeng Bo-en Pharmaceutical, received an approval certificate from Chinese regulators for its veterinary tetanus antitoxin, according to a Friday Hong Kong bourse filing.The product is used to prevent and treat tetanus infections in animals by neutralizing tetanus toxin and providing passive immune protection to animals at risk of infection.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185086992","title":"Movement Alert｜Jiangxi Biologics Rises 9.52% in Regular Trading, Subsidiary Obtains Veterinary Tetanus Antitoxin Product Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1185086992","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185086992?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:58","pubTimestamp":1783043903,"startTime":"0","endTime":"0","summary":"On July 3, Jiangxi Biologics rose 9.52% in regular trading, trading at HKD 6.82/share, with turnover of HKD 1.8971 million.On the news front, the company announced that its wholly-owned subsidiary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131987482","title":"JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin","url":"https://stock-news.laohu8.com/highlight/detail?id=1131987482","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131987482?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:57","pubTimestamp":1783033063,"startTime":"0","endTime":"0","summary":"The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106495850","title":"Jiangxi Bio Gains Regulatory Green Light for Veterinary Tetanus Antitoxin, Expanding Animal Health Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1106495850","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106495850?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:43","pubTimestamp":1783032232,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648363981","title":"Jiangxi Institute of Biological Products - Subsidiary Obtains Approval Certificate for Veterinary Tetanus Antitoxin","url":"https://stock-news.laohu8.com/highlight/detail?id=2648363981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648363981?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:33","pubTimestamp":1783031593,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN43410J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174536464","title":"Movement Alert｜Jiangxi Biologics Falls 17.86% in Regular Trading, IPO Debut Breaks Below Issue Price on First Day of Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1174536464","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174536464?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:51","pubTimestamp":1782784266,"startTime":"0","endTime":"0","summary":"On June 30, Jiangxi Biologics fell 17.86% in regular trading, trading at HKD 8.9/share, with turnover of HKD 106 million.The company officially listed on the HKEX main board today at an issue price...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647586397","title":"Jiangxi Institute of Biological Products Slumps 34% in Hong Kong Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2647586397","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647586397?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:48","pubTimestamp":1782784131,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products' (HKG:6915) shares opened 33.9% below the offer price in a weak Hong Kong debut on Tuesday morning.The human tetanus antitoxin provider opened at HK$7.40 per share, compared with the offer price of HK$11.20.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647658688","title":"Jiangxi Bio Prices Hong Kong IPO at Midpoint, Raises HK$339 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647658688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647658688?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:43","pubTimestamp":1782783804,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products  will receive HK$338.8 million in net proceeds from its initial public offering in Hong Kong after pricing the shares at the midpoint of the indicative range, according to a Monday after-market disclosure.The human tetanus antitoxin provider issued 36.2 million shares at HK$11.20 each, the midpoint of the HK$9.33 to HK$13.06 price range.The Hong Kong public offering portion of the deal was 476.56 times subscribed, with 3.62 million shares allocated, while the international offering was 4.25 times subscribed, with roughly 32.6 million shares allocated.A cornerstone investor was allotted 4.46 million shares, representing 12.3% of the IPO shares.Jiangxi Bio is set to debut on the Hong Kong bourse today, June 30.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127838328","title":"JIANGXI BIO Makes Debut on Exchange with Significant Early Drop, Holding Leading Global TAT Market Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1127838328","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127838328?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:34","pubTimestamp":1782783248,"startTime":"0","endTime":"0","summary":"JIANGXI BIO (06915) commenced trading on the stock exchange today. The company's shares were priced at HK$11.2 each for its initial public offering, which involved the issuance of 36.2345 million...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110273110","title":"Stock Track | JIANGXI BIO Plummets 21.43% at Market Open as Hong Kong Debut Opens Well Below IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1110273110","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110273110?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:34","pubTimestamp":1782783240,"startTime":"0","endTime":"0","summary":"JIANGXI BIO's stock plummeted 21.43% at market open on Tuesday, as the biopharmaceutical company made its trading debut in Hong Kong.The sharp decline came after the company's shares were set to open...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133745181","title":"Jiangxi Bio Sets Final IPO Price at HK$11.2 per Share, Hong Kong Public Offering Heavily Oversubscribed","url":"https://stock-news.laohu8.com/highlight/detail?id=1133745181","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133745181?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:28","pubTimestamp":1782739706,"startTime":"0","endTime":"0","summary":"The final allocation results for the initial public offering of JIANGXI BIO (06915) have been announced.The company issued a total of 36.2345 million shares globally, with the Hong Kong public...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647728383","title":"Jiangxi Institute of Biological Products - Final Offer Price Under Global Offering Set at Hk$11.2 Per H Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2647728383","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647728383?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:15","pubTimestamp":1782738910,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125474288","title":"New Stock Pre-Listing Trading: JIANGXI BIO (06915) Drops Over 10% Initially, Resulting in a Loss per Board Lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1125474288","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125474288?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:28","pubTimestamp":1782721700,"startTime":"0","endTime":"0","summary":"Pre-listing trading for JIANGXI BIO (06915), which is scheduled to list on the Hong Kong exchange on Tuesday, June 30th, has commenced.As of the latest update, the indicative price in the pre-market...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147268844","title":"Jiangxi Bio Releases Updated Articles of Association Detailing Governance Structure, Share Capital and Dividend Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1147268844","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147268844?lang=en_us&edition=fundamental","pubTime":"2026-06-29 06:25","pubTimestamp":1782685523,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products Inc. (abbrev. “Jiangxi Bio”) has published its revised Articles of Association, setting out the company’s legal framework ahead of its planned Main Board...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126867996","title":"JIANGXI BIO Releases Updated Audit Committee Charter to Strengthen Governance and Oversight","url":"https://stock-news.laohu8.com/highlight/detail?id=1126867996","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126867996?lang=en_us&edition=fundamental","pubTime":"2026-06-29 06:24","pubTimestamp":1782685498,"startTime":"0","endTime":"0","summary":"JIANGXI BIO has published the “Terms of Reference of the Audit Committee under the Board of Directors,” detailing the structure, responsibilities and operating procedures of the committee as part of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108190371","title":"Jiangxi Bio Sets Out Strategy and Investment Committee Mandate to Bolster Governance Ahead of Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1108190371","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108190371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 06:24","pubTimestamp":1782685448,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products Inc. (abbreviated as Jiangxi Bio) has published the “Terms of Reference of the Strategy and Investment Committee under the Board of Directors,” establishing a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178821386","title":"Initial Public Offering Update: JIANGXI BIO (06915) Subscription Period Concludes with HK$10.4 Billion in Margin Financing, Oversubscribed 219 Times","url":"https://stock-news.laohu8.com/highlight/detail?id=1178821386","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178821386?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:33","pubTimestamp":1782369237,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm JIANGXI BIO (06915) has concluded its public share subscription period, which ran from June 22 to June 25, 2026. Market data indicates the offering has attracted HK$10.4...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104441491","title":"Jiangxi Bio's Hong Kong IPO: Dominant Market Share Fails to Mask Profitability Challenges, Rising VAT and Single-Product Reliance Weigh on Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1104441491","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104441491?lang=en_us&edition=fundamental","pubTime":"2026-06-24 14:41","pubTimestamp":1782283276,"startTime":"0","endTime":"0","summary":"The largest provider of human tetanus antitoxin (TAT) in China, JIANGXI BIO, has officially launched the global offering for its Hong Kong stock exchange listing. The company, with a dominant 65.8%...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","IPOS","BK4588","06915","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645010353","title":"Jiangxi Institute of Biological Products Seeks Up to HK$473 Million in Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2645010353","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645010353?lang=en_us&edition=fundamental","pubTime":"2026-06-22 10:32","pubTimestamp":1782095532,"startTime":"0","endTime":"0","summary":"Jiangxi Institute of Biological Products  launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$473.2 million.The Chinese antiserum company is offering 36.2 million H-shares at an indicative price range of HK$9.33 to HK$13.06 per share, according to a Hong Kong bourse filing.The offering comprises 3.62 million shares for Hong Kong investors and 32.61 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by June 26, with allocation results due by June 29, ahead of the company's planned trading debut on June 30.Net proceeds will be used to expand the company's production and research and development capabilities.The company secured one cornerstone investor who committed to purchasing HK$50 million worth of IPO shares.China International Capital Corp., China Merchants Securities, Futu Securities International, Guosen Securities, CMBC Securities, and Arta Asset Management a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06915","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}